SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Burzynski Research Institute Inc – ‘10-Q’ for 11/30/12 – EX-101.INS

On:  Monday, 1/14/13, at 4:49pm ET   ·   For:  11/30/12   ·   Accession #:  1104659-13-2307   ·   File #:  0-23425

Previous ‘10-Q’:  ‘10-Q’ on 10/15/12 for 8/31/12   ·   Next:  ‘10-Q’ on 7/15/13 for 5/31/13   ·   Latest:  ‘10-Q’ on 7/15/19 for 5/31/19

  in    Show  and    Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 1/14/13  Burzynski Research Institute Inc  10-Q       11/30/12   31:1.6M                                   Merrill Corp-MD/FA

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    237K 
 2: EX-31.1     Certification per Sarbanes-Oxley Act (Section 302)  HTML     16K 
 3: EX-31.2     Certification per Sarbanes-Oxley Act (Section 302)  HTML     16K 
 4: EX-32.1     Certification per Sarbanes-Oxley Act (Section 906)  HTML     14K 
 5: EX-32.2     Certification per Sarbanes-Oxley Act (Section 906)  HTML     14K 
13: EXCEL       XBRL IDEA Workbook -- Financial Report (.xls)        XLS    158K 
20: R1          Document and Entity Information                     HTML     33K 
15: R2          Balance Sheets                                      HTML     63K 
18: R3          Balance Sheets (Parenthetical)                      HTML     28K 
21: R4          Statements of Operations                            HTML     43K 
28: R5          Statement of Stockholders' Deficit                  HTML     28K 
16: R6          Statements of Cash Flows                            HTML     53K 
17: R7          Basis of Presentation                               HTML     25K 
14: R8          Economic Dependency                                 HTML     27K 
12: R9          Stock Options                                       HTML     27K 
29: R10         Loss Per Share                                      HTML     17K 
23: R11         Income Taxes                                        HTML     57K 
22: R12         Stock Options (Tables)                              HTML     17K 
25: R13         Income Taxes (Tables)                               HTML     51K 
26: R14         Basis of Presentation (Details)                     HTML     13K 
24: R15         Stock Options (Details)                             HTML     48K 
27: R16         Loss Per Share (Details)                            HTML     18K 
19: R17         Income Taxes (Details)                              HTML     49K 
30: XML         XBRL XML File -- Filing Summary                      XML     38K 
 6: EX-101.INS  XBRL Instance -- bzyr-20121130                       XML    238K 
 8: EX-101.CAL  XBRL Calculations -- bzyr-20121130_cal               XML     67K 
 9: EX-101.DEF  XBRL Definitions -- bzyr-20121130_def                XML     89K 
10: EX-101.LAB  XBRL Labels -- bzyr-20121130_lab                     XML    578K 
11: EX-101.PRE  XBRL Presentations -- bzyr-20121130_pre              XML    268K 
 7: EX-101.SCH  XBRL Schema -- bzyr-20121130                         XSD     56K 
31: ZIP         XBRL Zipped Folder -- 0001104659-13-002307-xbrl      Zip     45K 


EX-101.INS   —   XBRL Instance — bzyr-20121130


This exhibit is an XBRL XML File.


                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!-- Generated by IRIS Proton Version 4.0.2.1 -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:bzyr="http://www.burzynskiresearch.com/20121130" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
<link:schemaRef xlink:type="simple" xlink:href="bzyr-20121130.xsd"/>
<xbrli:context id="D2013Q3YTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2011-09-01 </xbrli:startDate>
<xbrli:endDate> 2011-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3YTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2011-03-01 </xbrli:startDate>
<xbrli:endDate> 2011-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-09-01 </xbrli:startDate>
<xbrli:endDate> 2012-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-02-28 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012Q3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q3_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q3_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q3_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q3YTD_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D1997Q3_M09_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockOptionsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 1996-09-01 </xbrli:startDate>
<xbrli:endDate> 1996-09-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D1998Q2_M06_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockOptionsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 1997-06-01 </xbrli:startDate>
<xbrli:endDate> 1997-06-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D1999Q2_M06_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockOptionsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 1998-06-01 </xbrli:startDate>
<xbrli:endDate> 1998-06-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q3YTD_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockOptionsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q3YTD_InternalRevenueServiceIRSMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:InternalRevenueServiceIRSMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q3YTD_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3_M0705_WorldwideMedicalConsultantsIncMember_CarigenLtdMem­ber">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-07-04 </xbrli:startDate>
<xbrli:endDate> 2012-07-05 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012Q3_M0705_WorldwideMedicalConsultantsIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-07-05 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q3_M0705_WorldwideMedicalConsultantsIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-07-04 </xbrli:startDate>
<xbrli:endDate> 2012-07-05 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q3_WorldwideMedicalConsultantsIncMember_CarigenLtdMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bzyr:WorldwideMedicalConsultantsIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bzyr:CarigenLtdMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-11-30 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="USD">
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Shares">
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Pure">
<xbrli:measure> xbrli:pure </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Item">
<xbrli:measure> bzyr:item </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USDPerShare">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<dei:EntityRegistrantName id="Tag1" contextRef="D2013Q3YTD"> BURZYNSKI RESEARCH INSTITUTE INC </dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Tag2" contextRef="D2013Q3YTD"> 0000724445 </dei:EntityCentralIndexKey>
<dei:DocumentType id="Tag3" contextRef="D2013Q3YTD"> 10-Q </dei:DocumentType>
<dei:DocumentPeriodEndDate id="Tag4" contextRef="D2013Q3YTD"> 2012-11-30 </dei:DocumentPeriodEndDate>
<dei:AmendmentFlag id="Tag5" contextRef="D2013Q3YTD"> false </dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate id="Tag6" contextRef="D2013Q3YTD"> --02-28 </dei:CurrentFiscalYearEndDate>
<dei:EntityCurrentReportingStatus id="Tag7" contextRef="D2013Q3YTD"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory id="Tag8" contextRef="D2013Q3YTD"> Smaller Reporting Company </dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding id="Tag9" decimals="INF" contextRef="I2013Q3" unitRef="Shares"> 131448444 </dei:EntityCommonStockSharesOutstanding>
<dei:DocumentFiscalYearFocus id="Tag10" contextRef="D2013Q3YTD"> 2013 </dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Tag11" contextRef="D2013Q3YTD"> Q3 </dei:DocumentFiscalPeriodFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag12" decimals="0" contextRef="I2012" unitRef="USD"> 17297 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AssetsCurrent id="Tag13" decimals="0" contextRef="I2012" unitRef="USD"> 17297 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Tag14" decimals="0" contextRef="I2012" unitRef="USD"> 3419 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets id="Tag15" decimals="0" contextRef="I2012" unitRef="USD"> 20716 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent id="Tag16" decimals="0" contextRef="I2012" unitRef="USD"> 12265 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Tag17" decimals="0" contextRef="I2012" unitRef="USD"> 49699 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:Liabilities id="Tag18" decimals="0" contextRef="I2012" unitRef="USD"> 61964 </us-gaap:Liabilities>
<us-gaap:CommonStockValue id="Tag19" decimals="0" contextRef="I2012" unitRef="USD"> 131449 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Tag20" decimals="0" contextRef="I2012" unitRef="USD"> 101428376 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Tag21" decimals="0" contextRef="I2012" unitRef="USD"> -101601073 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:LiabilitiesAndStockholdersEquity id="Tag22" decimals="0" contextRef="I2012" unitRef="USD"> 20716 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense id="Tag23" decimals="0" contextRef="D2012Q3" unitRef="USD"> 1764352 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:StockholdersEquity id="Tag24" decimals="0" contextRef="I2012" unitRef="USD"> -41248 </us-gaap:StockholdersEquity>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Tag25" decimals="0" contextRef="I2013Q3" unitRef="USD"> 19509 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Tag26" decimals="0" contextRef="I2012" unitRef="USD"> 18996 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:CommonStockSharesAuthorized id="Tag27" decimals="INF" contextRef="I2012" unitRef="Shares"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Tag28" decimals="INF" contextRef="I2012" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Tag29" decimals="INF" contextRef="I2012" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare id="Tag30" decimals="INF" contextRef="I2012" unitRef="USDPerShare"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare id="Tag31" decimals="INF" contextRef="I2013Q3" unitRef="USDPerShare"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Tag32" decimals="INF" contextRef="I2013Q3" unitRef="Shares"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Tag33" decimals="INF" contextRef="I2013Q3" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Tag34" decimals="INF" contextRef="I2013Q3" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:GeneralAndAdministrativeExpense id="Tag35" decimals="0" contextRef="D2012Q3" unitRef="USD"> 75451 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization id="Tag36" decimals="0" contextRef="D2012Q3" unitRef="USD"> 177 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:OperatingExpenses id="Tag37" decimals="0" contextRef="D2012Q3" unitRef="USD"> 1839980 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Tag38" decimals="0" contextRef="D2012Q3" unitRef="USD"> -1839980 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:ResearchAndDevelopmentExpense id="Tag39" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 4939748 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag40" decimals="0" contextRef="D2012Q3" unitRef="USD"> -1839980 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasicAndDiluted id="Tag41" decimals="2" contextRef="D2012Q3" unitRef="USDPerShare"> -0.01 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag42" decimals="0" contextRef="D2012Q3" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:OperatingExpenses id="Tag43" decimals="0" contextRef="D2013Q3" unitRef="USD"> 1529741 </us-gaap:OperatingExpenses>
<us-gaap:GeneralAndAdministrativeExpense id="Tag44" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 185623 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag45" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -5125902 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:OperatingExpenses id="Tag46" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 5125902 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Tag47" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -5125902 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:DepreciationDepletionAndAmortization id="Tag48" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 531 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:EarningsPerShareBasicAndDiluted id="Tag49" decimals="2" contextRef="D2012Q3YTD" unitRef="USDPerShare"> -0.04 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag50" decimals="0" contextRef="D2012Q3YTD" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:OperatingExpenses id="Tag51" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 5004042 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Tag52" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -5003942 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<bzyr:ClinicalTrialExpensesPaid id="Tag53" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 4762103 </bzyr:ClinicalTrialExpensesPaid>
<us-gaap:IncreaseDecreaseInAccountsPayable id="Tag54" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -35638 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="Tag55" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 10365 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag56" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -388541 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:ProceedsFromContributedCapital id="Tag57" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 387199 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag58" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 387199 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag59" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -1342 </us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="Tag60" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 159896 </us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag61" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -538343 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag62" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 523682 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag63" decimals="0" contextRef="I2011" unitRef="USD"> 17476 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag64" decimals="0" contextRef="I2012Q3" unitRef="USD"> 16134 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:StockholdersEquity id="Tag65" decimals="0" contextRef="I2012_CommonStockMember" unitRef="USD"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Tag66" decimals="0" contextRef="I2012_AdditionalPaidInCapitalMember" unitRef="USD"> 101428376 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Tag67" decimals="0" contextRef="I2012_RetainedEarningsMember" unitRef="USD"> -101601073 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Tag68" decimals="0" contextRef="I2013Q3_CommonStockMember" unitRef="USD"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Tag69" decimals="INF" contextRef="I2012_CommonStockMember" unitRef="Shares"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Tag70" decimals="0" contextRef="I2013Q3_AdditionalPaidInCapitalMember" unitRef="USD"> 106388682 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Tag71" decimals="0" contextRef="I2013Q3_RetainedEarningsMember" unitRef="USD"> -106605015 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Tag72" decimals="INF" contextRef="I2013Q3_CommonStockMember" unitRef="Shares"> 131448444 </us-gaap:SharesOutstanding>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed id="Tag73" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 523682 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed id="Tag74" decimals="0" contextRef="D2013Q3YTD_AdditionalPaidInCapitalMember" unitRef="USD"> 523682 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses id="Tag75" decimals="0" contextRef="D2013Q3YTD_AdditionalPaidInCapitalMember" unitRef="USD"> -4276728 </bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Tag76" contextRef="D2013Q3YTD">
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.75in"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">NOTE A.</font></i></b><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt; FONT-STYLE: italic" size="1">                     </font></i></b> <b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic" size="2">BASIS OF PRESENTATION</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The financial statements of Burzynski Research Institute, Inc., a Delaware corporation (the “Company”), include expenses incurred directly by S.R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) within his medical practice, related to the conduct of U.S. Food and Drug Administration (“FDA”) approved clinical trials for Antineoplaston drugs used in the treatment of cancer.  These expenses have been reported as research and development costs and as additional paid-in capital.  Cash contributions received from Dr. Burzynski, which are used to fund general operating expenses, have also been reported as additional paid-in capital. Expenses related to Dr. Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements.  Dr. Burzynski is the President, Chairman of the Board and owner of 80.9% of the outstanding stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons,” which he has licensed to the Company.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company and Dr. Burzynski have entered into various agreements which provide the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once an Antineoplaston drug is approved for sale by the FDA.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer.  The Company is currently conducting clinical trials on various Antineoplastons in accordance with FDA regulations. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of November 30, 2012 and February 29, 2012, results of operations for the three and nine months ended November 30, 2012 and 2011 and cash flows for the nine months ended November 30, 2012 and 2011.  All adjustments are of a normal recurring nature.  The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.  These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 29, 2012.</font></p>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag77" contextRef="D2013Q3YTD">
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.75in"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">NOTE B.</font></i></b><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt; FONT-STYLE: italic" size="1">                     </font></i></b> <b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic" size="2">ECONOMIC DEPENDENCY</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit.  Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice.  A portion of Dr. Burzynski’s patients are admitted and treated as part of the clinical trial programs, which are regulated by the FDA.  The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA.  These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA. In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.  The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">It is also the intention of the directors and management to seek additional capital through the sale of securities.  The proceeds from such sales will be used to fund the Company’s operating deficit until it achieves positive operating cash flow.  There can be no assurance that the Company will be able to raise such additional capital.</font></p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Tag78" contextRef="D2013Q3YTD">
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.75in"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">NOTE C.</font></i></b><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt; FONT-STYLE: italic" size="1">                     </font></i></b> <b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic" size="2">STOCK OPTIONS</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">At November 30, 2012, the Company had one stock-based employee compensation plan, which is described below.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company. </font> <font style="FONT-SIZE: 10pt" size="2">The options vested as follows:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <table style="MARGIN-LEFT: 1.5in; WIDTH: 36.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="36%" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.86%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">400,000 options</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 6.82%; PADDING-TOP: 0in" valign="bottom" width="6%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 43.58%; PADDING-TOP: 0in" valign="bottom" width="43%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">September 14, 1996</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.72%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.86%; PADDING-TOP: 0in" valign="top" width="46%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">100,000 options</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.82%; PADDING-TOP: 0in" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 43.58%; PADDING-TOP: 0in" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">June 1, 1997</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.72%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.86%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">100,000 options</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 6.82%; PADDING-TOP: 0in" valign="bottom" width="6%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 43.58%; PADDING-TOP: 0in" valign="bottom" width="43%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">June 1, 1998</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.72%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The options are valid in perpetuity.  In addition, for a period of 10 years from the grant date, they increase in the same percentage of any new shares of stock issued; however, no shares were issued during such 10-year periods from the grant dates.  None of the options have been exercised as of November 30, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) 718, “Compensation — Stock Compensation,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee officers based on estimated fair values as of the date of grant. Compensation expense is recognized on a straight-line basis over the requisite service period.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company accounts for share-based payments to non-employees, with guidance provided by FASB ASC 505-50, “Equity-Based Payments to Non-Employees.”</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company did not grant any options and no options previously granted vested in any of the periods presented in these financial statements. Thus, there was no effect on net loss and loss per share regarding the provisions of FASB ASC 718 in any of the periods presented</font><font style="FONT-SIZE: 10pt" size="2">.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to 10% of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of 2,000,000 shares of the Company’s Common Stock, exercisable at $0.10 per share with a ten year exercise period, with 1,000,000 shares vesting upon execution of the agreement and the remaining 1,000,000 shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. The fair market value of the vested warrants as of the date of grant was measured using the Black-Scholes option pricing model and totaled approximately $160,000 or $0.16 per warrant. As of November 30, 2012, none of the aforementioned warrants have been exercised and none of the remaining 1,000,000 shares have vested as a result of a closing of a transaction by SRB.</font></p>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:EarningsPerShareTextBlock id="Tag79" contextRef="D2013Q3YTD">
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.75in"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">NOTE D.</font></i></b><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt; FONT-STYLE: italic" size="1">                     </font></i></b> <b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic" size="2">LOSS PER SHARE</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company accounts for loss per share in accordance with FASB ASC 260, “Earnings per Share.” Basic loss per share amounts are calculated by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the periods, including the dilutive effect of all common stock equivalents. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported. During the three and nine month periods ended November 30, 2012 and 2011, respectively, 1,600,000 and 600,000 warrants and stock options were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.</font></p>
</us-gaap:EarningsPerShareTextBlock>
<us-gaap:CommitmentsAndContingencies id="Tag80" xsi:nil="true" contextRef="I2012" unitRef="USD"/>
<us-gaap:CommitmentsAndContingencies id="Tag81" xsi:nil="true" contextRef="I2013Q3" unitRef="USD"/>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="Tag82" contextRef="D2013Q3YTD">
<table style="MARGIN-LEFT: 0.5in; WIDTH: 83.32%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="83%" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 31.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="31%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Three Months Ended November 30,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expected income tax benefit</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.36%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.04%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(</font><font style="FONT-SIZE: 10pt" size="2">520,112</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.36%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.08%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(625,594</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Effect of expenses deducted directly by Dr. Burzynski</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">520,112</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.44%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">625,594</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Nondeductible expenses and other adjustments</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19,231</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.44%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6,018</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Change in valuation allowance</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(19,231</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.44%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(6,018</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">State tax</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Income tax expense</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.04%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.08%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <table style="MARGIN-LEFT: 0.5in; WIDTH: 83.32%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="83%" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Nine Months Ended November 30,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expected income tax benefit</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.1%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(1,701,340</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.1%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(1,742,807</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Effect of expenses deducted directly by Dr. Burzynski</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,701,340</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,742,807</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Nondeductible expenses and other adjustments</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">69,202</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(7,955</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Change in valuation allowance</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(69,202</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,955</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">State tax</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Income tax expense</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.1%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.1%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table>
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans id="Tag83" decimals="INF" contextRef="D2013Q3YTD" unitRef="Item"> 1 </bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Tag84" decimals="0" contextRef="D2013Q3" unitRef="USD"> -1529741 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag85" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -14661 </us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag86" decimals="INF" contextRef="D1997Q3_M09_StockOptionsMember" unitRef="Shares"> 600000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag87" decimals="2" contextRef="D1997Q3_M09_StockOptionsMember" unitRef="USDPerShare"> 0.35 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod id="Tag88" decimals="INF" contextRef="D1997Q3_M09_StockOptionsMember" unitRef="Shares"> 400000 </bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod>
<bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod id="Tag89" decimals="INF" contextRef="D1998Q2_M06_StockOptionsMember" unitRef="Shares"> 100000 </bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod>
<bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod id="Tag90" decimals="INF" contextRef="D1999Q2_M06_StockOptionsMember" unitRef="Shares"> 100000 </bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod>
<bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPeriodForWhichAwardsIncreaseProportionatelyToNewIssues id="Tag91" contextRef="D2013Q3YTD_StockOptionsMember"> P10Y </bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPeriodForWhichAwardsIncreaseProportionatelyToNewIssues>
<bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination id="Tag92" contextRef="D2013Q3YTD_InternalRevenueServiceIRSMember"> P3Y </bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Tag93" decimals="INF" contextRef="D2013Q3YTD" unitRef="Pure"> 0.34 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="Tag94" decimals="0" contextRef="D2012Q3" unitRef="USD"> -625594 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationDeductions id="Tag95" decimals="0" contextRef="D2012Q3" unitRef="USD"> -625594 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="Tag96" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -1742807 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationDeductions id="Tag97" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -1742807 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense id="Tag98" decimals="0" contextRef="D2012Q3" unitRef="USD"> 6018 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Tag99" decimals="0" contextRef="D2012Q3" unitRef="USD"> -6018 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense id="Tag100" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> -7955 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Tag101" decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 7955 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsNet id="Tag102" decimals="0" contextRef="I2013Q3" unitRef="USD"> 0 </us-gaap:DeferredTaxAssetsNet>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Tag103" decimals="0" contextRef="I2013Q3" unitRef="USD"> 277812 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:OperatingLossCarryforwards id="Tag104" decimals="0" contextRef="I2013Q3" unitRef="USD"> 672332 </us-gaap:OperatingLossCarryforwards>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag105" decimals="0" contextRef="D2013Q3" unitRef="USD"> -1529741 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:OtherNonoperatingIncome id="Tag106" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 100 </us-gaap:OtherNonoperatingIncome>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock id="Tag107" contextRef="D2013Q3YTD">
<p style="MARGIN: 0in 0in 0pt 0.5in"> </p> <table style="MARGIN-LEFT: 1.5in; WIDTH: 291px; BORDER-COLLAPSE: collapse; HEIGHT: 68px" cellspacing="0" cellpadding="0" width="291" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.86%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">400,000 options</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 6.82%; PADDING-TOP: 0in" valign="bottom" width="6%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 43.58%; PADDING-TOP: 0in" valign="bottom" width="43%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">September 14, 1996</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.72%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.86%; PADDING-TOP: 0in" valign="top" width="46%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">100,000 options</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.82%; PADDING-TOP: 0in" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 43.58%; PADDING-TOP: 0in" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">June 1, 1997</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.72%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.86%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">100,000 options</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 6.82%; PADDING-TOP: 0in" valign="bottom" width="6%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 43.58%; PADDING-TOP: 0in" valign="bottom" width="43%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">June 1, 1998</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.72%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr></table>
</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
<bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard id="Tag108" decimals="3" contextRef="I2013Q3" unitRef="Pure"> 0.809 </bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard>
<us-gaap:IncomeTaxDisclosureTextBlock id="Tag109" contextRef="D2013Q3YTD">
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.75in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">NOTE  E.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">                </font></b> <b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic" size="2">INCOME TAXES</font></i></b></p> <p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company follows the provisions of FASB ASC 740-10, “<i>Accounting for Uncertainty in Income Taxes</i>”.  The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The federal income tax returns of the Company for 2011, 2010, and 2009 are subject to examination by the IRS, generally for three years after they are filed.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The actual provision for income tax for the three and nine month periods ended November 30, 2012 and 2011, respectively, differ from the amounts computed by applying the U.S. federal income tax rate of 34% to the pretax loss as a result of the following:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <table style="MARGIN-LEFT: 0.5in; WIDTH: 83.32%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="83%" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 31.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="31%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Three Months Ended November 30,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expected income tax benefit</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.36%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.04%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(</font><font style="FONT-SIZE: 10pt" size="2">520,112</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.36%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.08%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(625,594</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Effect of expenses deducted directly by Dr. Burzynski</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">520,112</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.44%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">625,594</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Nondeductible expenses and other adjustments</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19,231</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.44%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6,018</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Change in valuation allowance</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(19,231</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.44%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(6,018</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">State tax</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.78%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Income tax expense</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.04%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.08%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.38%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <table style="MARGIN-LEFT: 0.5in; WIDTH: 83.32%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="83%" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Nine Months Ended November 30,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expected income tax benefit</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.1%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(1,701,340</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.1%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(1,742,807</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Effect of expenses deducted directly by Dr. Burzynski</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,701,340</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,742,807</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Nondeductible expenses and other adjustments</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">69,202</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(7,955</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Change in valuation allowance</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(69,202</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.4%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,955</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">State tax</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.22%; PADDING-TOP: 0in" valign="top" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Income tax expense</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.1%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.1%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"></font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.98%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">At November 30, 2012, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $277,812.  The Company’s ability to utilize net operating loss carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income.  The Company has no historical earnings on which to base an expectation of future taxable income.  Accordingly, a valuation allowance for deferred tax assets has been provided.  At November 30, 2012, the Company had net operating loss carryforwards available to offset future taxable income in the amount of $672,332, which may be carried forward and will expire if not used between 2013 and 2033 in varying amounts</font><font style="FONT-SIZE: 10pt" size="2">.</font></p>
</us-gaap:IncomeTaxDisclosureTextBlock>
<bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses id="Tag110" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -4276728 </bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag111" decimals="0" contextRef="D2013Q3YTD_RetainedEarningsMember" unitRef="USD"> -5003942 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement id="Tag112" decimals="2" contextRef="D2012Q3_M0705_WorldwideMedicalConsultantsIncMember_CarigenLtdMem­ber" unitRef="Pure"> 0.10 </bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="Tag113" decimals="2" contextRef="I2012Q3_M0705_WorldwideMedicalConsultantsIncMember" unitRef="USDPerShare"> 0.10 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
<bzyr:ClassOfWarrantOrRightsExercisePeriod id="Tag114" contextRef="D2012Q3_M0705_WorldwideMedicalConsultantsIncMember"> P10Y </bzyr:ClassOfWarrantOrRightsExercisePeriod>
<bzyr:SharesVestingUponExecutionOfAgreement id="Tag115" decimals="INF" contextRef="D2012Q3_M0705_WorldwideMedicalConsultantsIncMember" unitRef="Shares"> 1000000 </bzyr:SharesVestingUponExecutionOfAgreement>
<bzyr:ClassOfWarrantOrRightNumberOfSecuritiesToBeCalledByWarrantsOrRightsWMCPaymentConsideration id="Tag116" decimals="INF" contextRef="D2012Q3_M0705_WorldwideMedicalConsultantsIncMember" unitRef="Shares"> 2000000 </bzyr:ClassOfWarrantOrRightNumberOfSecuritiesToBeCalledByWarrantsOrRightsWMCPaymentConsideration>
<bzyr:RemainingSharesToVestUponFirstClosingOfAgreement id="Tag117" decimals="INF" contextRef="D2012Q3_M0705_WorldwideMedicalConsultantsIncMember_CarigenLtdMem­ber" unitRef="Shares"> 1000000 </bzyr:RemainingSharesToVestUponFirstClosingOfAgreement>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="Tag118" decimals="0" contextRef="D2013Q3YTD_AdditionalPaidInCapitalMember" unitRef="USD"> 159896 </us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag119" decimals="0" contextRef="D2013Q3YTD" unitRef="Shares"> 1600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag120" decimals="0" contextRef="D2013Q3" unitRef="Shares"> 1600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<bzyr:WarrantOrRightFairValuePerWarrant id="Tag121" decimals="2" contextRef="I2012Q3_M0705_WorldwideMedicalConsultantsIncMember" unitRef="USDPerShare"> 0.16 </bzyr:WarrantOrRightFairValuePerWarrant>
<bzyr:WarrantsOrRightsFairValue id="Tag122" decimals="INF" contextRef="I2012Q3_M0705_WorldwideMedicalConsultantsIncMember" unitRef="USD"> 160000 </bzyr:WarrantsOrRightsFairValue>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="Tag123" decimals="0" contextRef="D2013Q3" unitRef="USD"> -520112 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationDeductions id="Tag124" decimals="0" contextRef="D2013Q3" unitRef="USD"> -520112 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense id="Tag125" decimals="0" contextRef="D2013Q3" unitRef="USD"> 19231 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Tag126" decimals="0" contextRef="D2013Q3" unitRef="USD"> -19231 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="Tag127" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -1701340 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationDeductions id="Tag128" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -1701340 </us-gaap:IncomeTaxReconciliationDeductions>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense id="Tag129" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 69202 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Tag130" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -69202 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxExpenseBenefit id="Tag131" decimals="0" contextRef="D2013Q3" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit id="Tag132" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag133" decimals="0" contextRef="I2013Q3" unitRef="USD"> 2636 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AssetsCurrent id="Tag134" decimals="0" contextRef="I2013Q3" unitRef="USD"> 2636 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Tag135" decimals="0" contextRef="I2013Q3" unitRef="USD"> 2906 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets id="Tag136" decimals="0" contextRef="I2013Q3" unitRef="USD"> 5542 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent id="Tag137" decimals="0" contextRef="I2013Q3" unitRef="USD"> 52977 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Tag138" decimals="0" contextRef="I2013Q3" unitRef="USD"> 37449 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:Liabilities id="Tag139" decimals="0" contextRef="I2013Q3" unitRef="USD"> 90426 </us-gaap:Liabilities>
<us-gaap:CommonStockValue id="Tag140" decimals="0" contextRef="I2013Q3" unitRef="USD"> 131449 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Tag141" decimals="0" contextRef="I2013Q3" unitRef="USD"> 106388682 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Tag142" decimals="0" contextRef="I2013Q3" unitRef="USD"> -106605015 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity id="Tag143" decimals="0" contextRef="I2013Q3" unitRef="USD"> -84884 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Tag144" decimals="0" contextRef="I2013Q3" unitRef="USD"> 5542 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense id="Tag145" decimals="0" contextRef="D2013Q3" unitRef="USD"> 1430406 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Tag146" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 4465736 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Tag147" decimals="0" contextRef="D2013Q3" unitRef="USD"> 99164 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Tag148" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 537793 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization id="Tag149" decimals="0" contextRef="D2013Q3" unitRef="USD"> 171 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization id="Tag150" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 513 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag151" decimals="0" contextRef="D2013Q3" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag152" decimals="0" contextRef="D2013Q3YTD" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Tag153" decimals="2" contextRef="D2013Q3" unitRef="USDPerShare"> -0.01 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Tag154" decimals="2" contextRef="D2013Q3YTD" unitRef="USDPerShare"> -0.04 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag155" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -5003942 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<bzyr:ClinicalTrialExpensesPaid id="Tag156" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 4276728 </bzyr:ClinicalTrialExpensesPaid>
<us-gaap:IncreaseDecreaseInAccountsPayable id="Tag157" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 40712 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="Tag158" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> -12250 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:ProceedsFromContributedCapital id="Tag159" decimals="0" contextRef="D2013Q3YTD" unitRef="USD"> 523682 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag160" decimals="0" contextRef="D2012Q3" unitRef="Shares"> 600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag161" decimals="0" contextRef="D2012Q3YTD" unitRef="Shares"> 600000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<bzyr:SharesNonvestedAsResultOfClosingOfTransaction id="Tag163" decimals="INF" contextRef="I2013Q3_WorldwideMedicalConsultantsIncMember_CarigenLtdMember" unitRef="Shares"> 1000000 </bzyr:SharesNonvestedAsResultOfClosingOfTransaction>
<us-gaap:IncomeTaxExpenseBenefit decimals="0" contextRef="D2012Q3YTD" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit decimals="0" contextRef="D2012Q3" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>
</xbrli:xbrl>
  Top
Filing Submission 0001104659-13-002307   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2019 Fran Finnegan & Company.  All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Aug. 20, 12:24:06.1pm ET